PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer

Jaanika Narits a,⇑, Hannes Tamm b,c, Jana Jaal a,d

a Department of Hematology and Oncology, University of Tartu, Tartu, Estonia
b Pathology Service, Tartu University Hospital, Tartu, Estonia
c Chair of Pathological Anatomy, University of Tartu, Tartu, Estonia
d Hematology and Oncology Clinic, Department of Radiotherapy and Oncological Therapy, Tartu University Hospital, Tartu, Estonia

Article info

Article history:
Received 1 January 2020
Revised 5 April 2020
Accepted 6 April 2020
Available online 7 April 2020

Keywords:
Nsclc
Metastases
Radiotherapy
PD-L1
Pembrolizumab

Abstract

We report on a 67-year old male with advanced stage lung adenocarcinoma (initially PD-L1 negative, EGFR and ALK negative) diagnosed in 2014. The patient received 4 lines of palliative chemotherapy from 2014 to 2017, however the disease progressed. In 2015, he also received palliative hypofractionated radiotherapy to a mediastinal mass, which was causing discomfort and pain. Since there was some data, that radiotherapy could induce PD-L1 expression, a new biopsy was taken in 2017 from the irradiated mediastinal mass. Subsequent pathologic report revealed that PD-L1 status was turned to be highly positive, with tumor proportion score of 100%. Similar high expression of PD-L1 was detected in a new metastasis in the duodenum, which was excised due to a duodenal perforation in 2017. From October 2017 to October 2019, the patient had 2-years of treatment (32 courses) with pembrolizumab and has had a positive effect (partial response) on all the lesions and following stabilization of the disease. Currently, this patient is under follow up and he is in a good condition without any complaints. Last CT-scan in March 2020 showed persisting partial response.

© 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Despite the development of diagnostic methods, most of non-small cell lung cancer (nsclc) cases are still diagnosed in advanced stages with distant metastases [1].

For metastatic stage IV nsclc, drug therapies are mainly used [2,3]. The choice of medical treatment is based on factors such as histology, molecular pathology, age, performance status, comorbidities and the patient’s preferences. Possible drugs include tyrosine kinase inhibitors for EGFR (Epidermal Growth Factor Receptor) mutation positive tumors, specific inhibitors for ALK (Anaplastic Lymphoma Kinase) rearranged nsclc, immunotherapy with immune checkpoint inhibitor Pembrolizumab for PD-L1 (Programmed Death Ligand-1) strongly positive tumors (PD-L1 tumor proportion score, TPS ≥50%) or immunotherapy and chemotherapy combinations.

Next to these systemic nsclc treatments, patients with metastatic lung cancer can be treated with thoracic radiotherapy to relieve tumor related symptoms (hemoptysis, bronchial obstruction, cough, shortness of breath, and chest pain) and to improve health related quality of life [4]. More recently, the addition of local radiotherapy has also been shown to improve treatment efficacy and patient survival compared to chemotherapy alone [5].

We present here a case, where radiotherapy not only resulted in a long-lasting treatment response but also could have induced PD-L1 expression in initially PD-L1 negative tumor enabling thereby subsequent effective immunotherapy with pembrolizumab despite of previously received 4 lines of systemic chemotherapy regimens.

2. Case report

A consent was obtained from the patient to present his case. This case describes a 67–year old Caucasian male with no previous illnesses, ECOG 0–1, who was diagnosed with advanced stage IV adenocarcinoma of the lung in July 2014. At the time of diagnosis, the patient had a peripheral tumor in the upper lobe of the right lung with metastasis to the lymph nodes in the upper right mediastinum, right axilla and neck. The patient complained about a mass on the neck and was referred to a general surgeon by his general physician. An enlarged supraclavicular lymph node was
excised and the initial diagnosis of lung adenocarcinoma was obtained. The tumor was EGFR, ALK negative and PD-L1 negative (tumor proportion score, TPS 0%; Fig. 1A).

Treatment timeline of this patient is depicted in Fig. 2. The patient was initially treated with palliative cisplatin and gemcitabine combination chemotherapy for 4 courses. Cisplatin was changed to carboplatin from the second course. Since the patient had a positive effect in primary tumor and all the metastases, we proceeded with maintenance therapy with pemetrexed. After 9 courses, the computed tomography (CT) scan in June 2015 showed negative dynamics and new axillary metastases. Due to progression, patient received 3rd line chemotherapy with docetaxel for 6 courses. In December 2015, the right upper mediastinal lymph node mass had enlarged and caused discomfort and chest pain for the patient. To relieve the symptoms, he received hypofractionated radiotherapy to the upper mediastinal mass 45 Gy total in 15 fractions (radiotherapy plan is shown in Fig. 3). In the beginning of 2016, after the palliative radiotherapy, we continued with chemotherapy again with carboplatin plus gemcitabine, since during this 1st line regimen the disease did not progress. The patient received 6 courses of palliative chemotherapy and a CT scan in September 2016 showed a stable disease. He continued with follow-up. CT scan in February 2017 showed again a progression and enlargement of the right upper mediastinal mass. Since it had been 9 months since the last chemotherapy, we continued with the carboplatin plus gemcitabine regime again for 6 courses. CT scan in August 2017 showed a further progression. Previously irradiated right upper mediastinal mass was enlarged even more and infiltrated the right v. subclavia; v. brachiocephalica; v. azygos and v. cava superior. In September 2017 we decided to re-biopsy the irradiated mass in the right upper mediastinum (CT-guided transthoracic biopsy) due to the knowledge that radiotherapy could induce PD-L1 expression. Pathologic report confirmed that patient had metastatic adenocarcinoma of the lung, however, the expression of PD-L1 turned out to be highly positive (TPS 100%; Fig. 1B). Afterwards, the patient submitted an application to Estonian cancer treatment foundation “The Gift of Life” to get a reimbursement for immunotherapy with pembrolizumab since it was not reimbursed by national healthcare system at that time. Meanwhile, an emergency operation was performed on 30th of September 2017 because of duodenal perforation. The perforation was due to a mass in the duodenum. A piece of the duodenum with the attached mass was excised and the histology confirmed metastasis of lung adenocarcinoma, also PD-L1 highly positive (TPS 100%; Fig. 1C). In October 2017, the patient was in good condition, ECOG 1 and highly interested in proceeding the treatment. Since the charity fund “The Gift of Life” agreed to cover the cost of immunotherapy, the treatment with pembrolizumab was started. CT scan in December 2017 showed a positive effect (partial response) since the right upper mediastinal mass was decreased in size. We continued with pembrolizumab, which the patient tolerated very well without any immune-related adverse events. In October 2019 the patient has had 2-years of treatment (32 courses) with pembrolizumab and has had a positive effect (partial response) on all the lesions and following stabilization of the disease. After stopping immunotherapy, the patient was in a good condition, ECOG 0, returned to work and had no complaints. Currently, this patient is under follow up and the last CT-scan in March 2020 showed persisting partial response.

3. Discussion

From the start of immunotherapy in nsclc, numerous biomarkers to predict benefit from this type of treatment have been evaluated. These include markers such as blood neutrophil–lymphocyte ratio (NLR) as well as tumor mutational burden (TMB) [6,7]. Nevertheless, so far, the most studied biomarker in nsclc immunotherapy is an immunohistochemical expression level of PD-L1 on tumor cells, since several phase III clinical studies have reported better treatment responses in patients with PD-L1 positive tumors [8,9]. Additionally, the most remarkable treatment efficacy with immune checkpoint inhibitors have been seen in nsclc patients with high PD-L1 tumor proportion score (i.e. TPS ≥50%) [8,9].
Previous studies involving different world regions have revealed that approximately only one third of nsclc patients have tumors that express PD-L1 in high levels [3]. Moreover, in Europe, much smaller proportion of nsclc patients (11%) have tumors that express PD-L1 on ≥50% of cancer cells [10]. Latter has raised a number of questions whether tumor microenvironment can be changed and PD-L1 expression induced so that more nsclc patients could benefit from modern immunotherapy.

In nsclc, the effect of chemotherapy on tumor cell PD-L1 expression has been previously investigated in patients receiving neoadjuvant chemotherapy. However, the results are still controversial, showing decrease in PD-L1 expression [11], no significant changes...
upregulated PD-L1 expression, or mixed results. These findings are also confused due to retrospective nature of reported studies as well as different and not clinically validated antibodies used for immunohistochemical detection of PD-L1. In contrast, studies on radiation-induced PD-L1 induction have been quite consistent. Growing number of preclinical studies indicate that irradiation induces PD-L1 expression on tumor cells. In general, radiotherapy-associated increases in tumor cell PD-L1 expression often occur early with peak levels detected within 24–96 h post-radiotherapy. In nsclc cells, radiation-induced PD-L1 expression has been seen as early as 1–2 h after single dose of 6 Gy, whereas 4 h after irradiation no further increases were seen. However, radiation-induced increase in PD-L1 expression in nsclc cells seems to be long-lasting since it has been reported 24 h after 2 fractions of 8.5 Gy and 72 h after 3 fractions of 2 Gy. These preclinical findings of radiation-induced PD-L1 induction are supported by a published clinical case report, where gradually increased PD-L1 expression has been detected in a nsclc patient brain metastasis after repeated radiotherapy. Additionally, some indirect evidence that radiotherapy may cause favourable changes in tumor microenvironment (e.g. induce PD-L1 expression) came from a published clinical study where compared to only immunotherapy-treated patients, longer progression-free survival (PFS) and overall survival (OS) were seen in patients that received prior pembrolizumab radiotherapy.

We present here the case, where radiotherapy not only resulted in a long-lasting treatment response but also could have induced PD-L1 expression in initially PD-L1 negative tumor enabling thereby subsequent effective immunotherapy with pembrolizumab despite of previously received 4 lines of systemic chemotherapy regimens. Without any doubt, radiotherapy is an important treatment modality that can be incorporated effectively into treatment schedules of metastatic nsclc. Whether radiotherapy should be added to medical treatments at initial treatment phase (e.g. to induce PD-L1 expression), after systemic treatment as consolidative local therapy or later on, should be clarified in future clinical trials.

Conclusion

We showed here that radiotherapy may not only result in a long-lasting treatment response but also could induce PD-L1 expression in initially PD-L1 negative tumor enabling thereby subsequent effective immunotherapy with pembrolizumab despite of previously received 4 lines of systemic chemotherapy regimens. Without any doubt, radiotherapy is an important treatment modality that can be incorporated effectively into treatment schedules of metastatic nsclc. Whether radiotherapy should be added to medical treatments at initial treatment phase (e.g. to induce PD-L1 expression), after systemic treatment as consolidative local therapy or later on, should be clarified in future clinical trials.

Acknowledgement

The patient and authors are grateful to Estonian cancer treatment foundation “The Gift of Life” for covering the cost of pembrolizumab.

Conflict of interest

Jaanika Narits and Hannes Tamm declare no competing interests.

Jana Jaal is an advisory board member for AstraZeneca and MSD and has received research funding from Astra Zeneca.

References

[1] Innos K, Oselin K, Laisaar T, Aareleid T. Patterns of survival and surgical treatment in lung cancer patients in Estonia by histologic type and stage, 1996–2016. Acta Oncol. 2019;1–8.
[2] Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2018;29:v192-v237.

[3] Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England J Med 2018;378:2078–92.

[4] Rodrigues G, Videtic GM, Sur R, Bezjak A, Bradley J, Hahn CA, et al. Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2011;1:60–71.

[5] Gomez DR, Tang C, Zhang J, Blumenschein Jr GR, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37:1558–65.

[6] Ren F, Zhao T, Liu B, Pan L. Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). Onco Targets Therapy 2019;12:4235–44.

[7] Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol 2019;16:341–55.

[8] Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England J Med 2016;375:1823–33.

[9] Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819–29.

[10] Paweleczk K, Piotrowska A, Ciesielska U, Jablonska K, Gietrzol-Plucinska N, Grzegorzolka J, et al. Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers. Int J Mol Sci 2019;20.